Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the wistar rat

1. The ability of N-ethyl (MDEA) and N-butyl (MDBA) analogues of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') to induce acute behavioural changes and increases in body temperature, and to cause serotonergic neurotoxicity, was assessed in young adult male Wistar rats. The in vitro ability of MDMA analogues to evoke presynaptic monoamine release from crude rat forebrain synaptosomal preparations pre-labelled with [3H]5-HT or [3H]DA was also measured. 2. In behavioural experiments, acute MDMA and MDEA (20 mg/kg, i.p.) significantly increased rat open-field locomotion scores, decreased open-field rearing, and induced stereotypy, Straub tail and head weaving. MDBA did not produce any of these behaviours. 3. After repeated dosing (8 x 20 mg/kg, i.p., twice daily for 4 days), MDMA > MDEA >> MDBA > or = saline at decreasing forebrain [3H]paroxetine binding levels and concentrations of 5-HT and 5-HIAA at 14 days post-treatment. None of the analogues caused any long-term changes in dopamine or noradrenaline concentrations in the forebrain. 4. Acute MDMA and MDEA (20 mg/kg, i.p.) produced significant acute increases in rat aural temperature compared with saline-treated animals, while 20 mg/kg MDBA caused no significant effects. 5. MDA, MDMA and MDEA were equipotent at inducing [3H]5-HT release from frontal cortex/hippocampal synaptosomes, while MDBA only evoked a significant release at 100 microM concentrations. The potency order for inducing [3H]DA release from striatal synaptosomes was MDA > MDMA > MDEA = MDBA. 6. This study shows that large N-alkyl substitution decreases the ability of MDMA analogues to evoke presynaptic 5-HT and DA release, induce acute hyperthermia, hyperlocomotion and behavioural changes, and cause long-term serotonergic neurotoxicity. 7. The structure-activity relationship data presented here indicate that the neurotoxic damage caused by substituted amphetamines requires a combination of acute hyperthermia and increased neurotransmitter release. Induction of one of these effects in isolation is not sufficient to cause serotonergic nerve terminal degradation.

[1]  P. Dyment,et al.  Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. , 1994, Journal of American college health : J of ACH.

[2]  M. P. Johnson,et al.  Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. , 1986, European journal of pharmacology.

[3]  J. O'Callaghan,et al.  Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat , 1991, Pharmacology Biochemistry and Behavior.

[4]  M. Colado,et al.  In vivo evidence against clomethiazole being neuroprotective against MDMA (‘ecstasy’)-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism , 1999, Neuropharmacology.

[5]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.

[6]  M. Geyer,et al.  Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. , 1988, The Journal of pharmacology and experimental therapeutics.

[7]  Y. Claustre,et al.  Characterization of [3H]paroxetine binding to rat cortical membranes. , 1985, European journal of pharmacology.

[8]  J. Langston,et al.  3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. , 1987, European journal of pharmacology.

[9]  M. Colado,et al.  In vivo evidence for free radical involvement in the degeneration of rat brain 5‐HT following administration of MDMA (‘ecstasy’) and p‐chloroamphetamine but not the degeneration following fenfluramine , 1997, British journal of pharmacology.

[10]  G. Ricaurte,et al.  Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.

[11]  G. Hanson,et al.  A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. , 1987, European journal of pharmacology.

[12]  J. Kelly,et al.  Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats , 1995, Pharmacology Biochemistry and Behavior.

[13]  M. P. Johnson,et al.  [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. , 1991, European journal of pharmacology.

[14]  A. R. Green,et al.  Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats , 1994, Neuropharmacology.

[15]  M. Geyer,et al.  The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[16]  G. Battaglia,et al.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  M. Colado,et al.  The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.

[18]  M. Pranzatelli,et al.  The relation of central 5-HT1A and 5-HT2 receptors: Low dose agonist-induced selective tolerance in the rat , 1991, Pharmacology Biochemistry and Behavior.

[19]  L. Seiden,et al.  Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.

[20]  D E Nichols,et al.  An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. , 1998, Neurotoxicology.

[21]  D. E. N. A. R. Oberlender STRUCTURE-ACTIVITY RELATIONSHIPS OF MPMA AND RELATED COMPOUNDS : A NEW CLASS OF PSYCHOACTIVE AGENTS ? , 2022 .

[22]  A. Shulgin,et al.  Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). , 1980, Journal of pharmaceutical sciences.

[23]  D. E. Nichols,et al.  Structure‐Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Drugs? a , 1990, Annals of the New York Academy of Sciences.

[24]  J. Nash Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. , 1990, Life sciences.

[25]  M. Spitzer,et al.  Psychological Effects of MDE in Normal Subjects , 1993, Neuropsychopharmacology.

[26]  C. J. Schmidt,et al.  5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. , 1991, The Journal of pharmacology and experimental therapeutics.

[27]  C. J. Schmidt,et al.  Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors , 1990, Brain Research.

[28]  D. Mckenna,et al.  3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine , 1991, Pharmacology Biochemistry and Behavior.

[29]  J. Nash,et al.  Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. , 1991, European journal of pharmacology.

[30]  M. Wheaton,et al.  THE EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE (MDMA, “ECSTASY”) ON MONOAMINERGIC NEUROTRANSMISSION IN THE CENTRAL NERVOUS SYSTEM , 1996, Progress in Neurobiology.

[31]  W. Lovenberg,et al.  In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. , 1987, Biochemical pharmacology.

[32]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[33]  L. Seiden,et al.  Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat , 1998, The Journal of Neuroscience.

[34]  M. Molliver Serotonergic Neuronal Systems: What Their Anatomic Organization Tells Us about Function , 1987, Journal of clinical psychopharmacology.

[35]  C. J. Schmidt Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. , 1987, European journal of pharmacology.

[36]  C. J. Schmidt,et al.  Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. , 1987, Biochemical pharmacology.

[37]  M. Colado,et al.  Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.

[38]  T. Greve,et al.  An automated direct-injection HPLC-method for the electrochemical/fluorimetric quantitation of monoamines and related compounds optimized for the screening of large numbers of animals. , 1986, Biomedical chromatography : BMC.

[39]  L. Seiden,et al.  Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. , 1985, Science.

[40]  B. Yamamoto,et al.  Mazindol Attenuates the 3,4‐Methylenedioxymethamphetamine‐Induced Formation of Hydroxyl Radicals and Long‐Term Depletion of Serotonin in the Striatum , 1999, Journal of neurochemistry.

[41]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[42]  J. Tracey,et al.  Ecstasy abuse in Ireland. , 1993, Irish medical journal.

[43]  M. Colado,et al.  The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy"). , 1999, Pharmacology & toxicology.

[44]  C. J. Schmidt,et al.  L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. , 1991, European journal of pharmacology.

[45]  S. Peroutka Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA , 1990, Topics in the Neurosciences.